MACK Merrimack Pharmaceuticals, Inc.

-0.04  -1%
Previous Close 3.44
Open 3.45
Price To book 0.00
Market Cap 450.25M
Shares 132,427,000
Volume 2,685,692
Short Ratio 13.80
Av. Daily Volume 2,023,140

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation due 2017.
HER2 negative metastatic breast cancer
Phase 2 data due 2018.
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
Cancer - HER2-positive locally advanced or metastatic breast cancer
Approved October 22, 2015.
Cancer - second line pancreatic
Phase 2 initiated mid Feb 2015. Data due in 2018.
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
Cancer - front line pancreatic

Latest News

  1. Merrimack Announces Management Change
  2. Edited Transcript of MACK earnings conference call or presentation 10-May-17 12:30pm GMT
  3. Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde
  4. Merrimack's (MACK) Reports Wider-than-Expected Q1 Loss
  5. Investor Network: Merrimack Pharmaceuticals, Inc. to Host Earnings Call
  6. Merrimack reports 1Q loss
  7. Merrimack Reports First Quarter 2017 Financial Results
  8. Merrimack Announces Timing of First Quarter 2017 Investor Conference Call
  9. What's in the Cards for Merrimack (MACK) in Q1 Earnings?
  10. Merrimack Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MACK) : April 19, 2017
  11. Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : April 18, 2017
  12. Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research
  13. Merrimack Declares $140M Special Dividend in Connection with Recently Completed Asset Sale
  14. Merrimack Launches as New, Refocused Research & Clinical Development Company with Resources to Advance Prioritized Lead Pipeline Candidates MM-121, MM-141 and MM-310
  15. Are Options Traders Betting on a Big Move in Merrimack (MACK) Stock?
  16. Merrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion
  17. Merrimack to Present at the 2017 American Association for Cancer Research Annual Meeting
  18. Merrimack (MACK) Starts Enrollment in Solid Tumors Study
  19. ​Merrimack asset sale prompts legal blowback